GlassScriptPhysician profile
Michelle S Jackson
NPI 1568479715
$680.41
in general payments reported to CMS, 2019-2025
23 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $12.63 · 2024: $96.56 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $205.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $153.37 | 2024-2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.52 | 2019 | |
| Pfizer INC. | $51.09 | 2019 | |
| Gilead Sciences, INC. | $39.06 | 2019 | |
| Endo Pharmaceuticals INC. | $38.50 | 2019 | |
| Astellas Pharma US INC | $36.34 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.67 | 2019 | |
| Novo Nordisk INC | $28.33 | 2024 | Wegovy |
| Amarin Pharma, INC. | $27.89 | 2019 | |
| Hikma Pharmaceuticals USA | $23.69 | 2019 | |
| Alkermes, INC. | $23.58 | 2025 | Aristada, Lybalvi |
| Astrazeneca Pharmaceuticals LP | $18.97 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.92 | 2019 | |
| Shire North American Group INC | $16.76 | 2019 | |
| Lilly USA, LLC | $16.35 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $15.22 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.19 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.99 | 2019 | |
| Horizon Therapeutics Plc | $12.82 | 2019 | |
| Eisai INC. | $12.81 | 2019 | |
| Abbott Laboratories | $12.63 | 2020 | |
| Grifols USA, LLC | $11.62 | 2019 | |
| Supernus Pharmaceuticals, INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.